Cost-utility of a specific collaborative group intervention for patients with functional somatic syndromes
Standard
Cost-utility of a specific collaborative group intervention for patients with functional somatic syndromes. / Konnopka, Alexander; König, Hans-Helmut; Kaufmann, Claudia; Egger, Nina; Wild, Beate; Szecsenyi, Joachim; Herzog, Wolfgang; Schellberg, Dieter; Schaefert, Rainer.
in: J PSYCHOSOM RES, Jahrgang 90, 11.2016, S. 43-50.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cost-utility of a specific collaborative group intervention for patients with functional somatic syndromes
AU - Konnopka, Alexander
AU - König, Hans-Helmut
AU - Kaufmann, Claudia
AU - Egger, Nina
AU - Wild, Beate
AU - Szecsenyi, Joachim
AU - Herzog, Wolfgang
AU - Schellberg, Dieter
AU - Schaefert, Rainer
N1 - Copyright © 2016 Elsevier Inc. All rights reserved.
PY - 2016/11
Y1 - 2016/11
N2 - BACKGROUND: Collaborative group intervention (CGI) in patients with functional somatic syndromes (FSS) has been shown to improve mental quality of life.OBJECTIVE: To analyse incremental cost-utility of CGI compared to enhanced medical care in patients with FSS.METHODS: An economic evaluation alongside a cluster-randomised controlled trial was performed. 35 general practitioners (GPs) recruited 300 FSS patients. Patients in the CGI arm were offered 10 group sessions within 3months and 2 booster sessions 6 and 12months after baseline. Costs were assessed via questionnaire. Quality adjusted life years (QALYs) were calculated using the SF-6D index, derived from the 36-item short-form health survey (SF-36). We calculated patients' net-monetary-benefit (NMB), estimated the treatment effect via regression, and generated cost-effectiveness acceptability curves.RESULTS: Using intention-to-treat analysis, total costs during the 12-month study period were 5777EUR in the intervention, and 6858EUR in the control group. Controlling for possible confounders, we found a small, but significant positive intervention effect on QALYs (+0.017; p=0.019) and an insignificant cost saving resulting from a cost-increase in the control group (-10.5%; p=0.278). NMB regression showed that the probability of CGI to be cost-effective was 69% for a willingness to pay (WTP) of 0EUR/QALY, increased to 92% for a WTP of 50,000EUR/QALY and reached the level of 95% at a WTP of 70,375EUR/QALY. Subgroup analyses yielded that CGI was only cost-effective in severe somatic symptom severity (PHQ-15≥15).CONCLUSION: CGI has a high probability to be a cost-effective treatment for FSS, in particular for patients with severe somatic symptom severity.
AB - BACKGROUND: Collaborative group intervention (CGI) in patients with functional somatic syndromes (FSS) has been shown to improve mental quality of life.OBJECTIVE: To analyse incremental cost-utility of CGI compared to enhanced medical care in patients with FSS.METHODS: An economic evaluation alongside a cluster-randomised controlled trial was performed. 35 general practitioners (GPs) recruited 300 FSS patients. Patients in the CGI arm were offered 10 group sessions within 3months and 2 booster sessions 6 and 12months after baseline. Costs were assessed via questionnaire. Quality adjusted life years (QALYs) were calculated using the SF-6D index, derived from the 36-item short-form health survey (SF-36). We calculated patients' net-monetary-benefit (NMB), estimated the treatment effect via regression, and generated cost-effectiveness acceptability curves.RESULTS: Using intention-to-treat analysis, total costs during the 12-month study period were 5777EUR in the intervention, and 6858EUR in the control group. Controlling for possible confounders, we found a small, but significant positive intervention effect on QALYs (+0.017; p=0.019) and an insignificant cost saving resulting from a cost-increase in the control group (-10.5%; p=0.278). NMB regression showed that the probability of CGI to be cost-effective was 69% for a willingness to pay (WTP) of 0EUR/QALY, increased to 92% for a WTP of 50,000EUR/QALY and reached the level of 95% at a WTP of 70,375EUR/QALY. Subgroup analyses yielded that CGI was only cost-effective in severe somatic symptom severity (PHQ-15≥15).CONCLUSION: CGI has a high probability to be a cost-effective treatment for FSS, in particular for patients with severe somatic symptom severity.
U2 - 10.1016/j.jpsychores.2016.09.001
DO - 10.1016/j.jpsychores.2016.09.001
M3 - SCORING: Journal article
C2 - 27772558
VL - 90
SP - 43
EP - 50
JO - J PSYCHOSOM RES
JF - J PSYCHOSOM RES
SN - 0022-3999
ER -